Summary: Vanda Pharmaceuticals reported a considerable decline in Q1 2024 product sales for Hetlioz, attributed to amplified generic levels of competition. The corporation is concentrating on expanding Hetlioz indications to include insomnia and jet lag disorder, even with … [Read more...]